GSPT1 and acute myeloid leukemia: Studies revealed that GSPT1 degradation induced by CC‐90009 triggered the activation of the integrated stress response pathway, resulting in acute apoptosis.[86, 104] In the Phase I clinical trial of CC‐90009 for relapsed/refractory (R/R) AML, its toxicity profile was characterized by dose‐limiting toxicities (e.g., hypotension, SIRS, pericarditis with tamponade), common grade 3/4 treatment‐emergent adverse events (e.g., hypocalcemia), along with severe infections and rare treatment‐related deaths, yet the overall toxicity was clinically manageable.